Pfizer has developed and launched eletriptan, a 5-HT1B/1D agonist, for the potential treatment of migraine with and without aura. Eletriptan has 6-fold greater affinity for the 5-HT1D receptor than sumatriptan, and a 3-fold greater affinity for the 5-HT1B receptor [249570]. Eletriptan pharmacology has also been evaluated in vitro in comparison with zolmitriptan (AstraZeneca plc) and naratriptan (GlaxoSmithKline plc) [290116].
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
greater affinity
8
eletriptan
4
eletriptan pfizer
4
pfizer pfizer
4
pfizer developed
4
developed launched
4
launched eletriptan
4
eletriptan 5-ht1b/1d
4
5-ht1b/1d agonist
4
agonist potential
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!